Dihydrokavain

Dihydrokavain (7,8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, CYP2C9 (IC50 = 130.95 μM), CYP2C19 (IC50 = 10.05 μM) and CYP3A4 (IC50 = 78.59 μM) . Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects[1][2][3][4][5].

Product Specifications

CAS Number

[587-63-3]

Product Name Alternative

7,8-Dihydrokawain; 7,8-Dihydrokavain; Marindinin

UNSPSC

12352005

Hazard Statement

H302

Target

COX; Cytochrome P450

Type

Natural Products

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Dihydrokavain.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C=C(OC)C[C@H](CCC2=CC=CC=C2)O1

Molecular Formula

C14H16O3

Molecular Weight

232.28

Precautions

H302

References & Citations

[1]Feltenstein MW, et al. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. Phytother Res. 2003 Mar;17 (3) :210-6.|[2]Rowe A, et al. Kavalactone pharmacophores for major cellular drug targets. Mini Rev Med Chem. 2011 Jan;11 (1) :79-83.|[3]Xia Q, et al. Phototoxicity of kava - formation of reactive oxygen species leading to lipid peroxidation and DNA damage. Am J Chin Med. 2012;40 (6) :1271-88.|[4]Bian T, et al. Kava as a Clinical Nutrient: Promises and Challenges. Nutrients. 2020 Oct 5;12 (10) :3044.|[5]Anke J, et al. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.) . J Ethnopharmacol. 2004 Aug;93 (2-3) :153-60.|[6]Jamieson DD, et al. The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol. 1990 Jul;17 (7) :495-507.